



Misys plc - Preliminary Results - 2007/08

Mike Lawrie, Chief Executive
24 July 2008

This communication contains forward-looking statements. Those forward-looking statements include all statements other than those made solely with respect to historical fact. Forward-looking statements may be identified by words such as “believes”, “expects”, “anticipates”, “estimates”, “projects”, “intends”, “should”, “seeks”, “future”, “continue”, or the negative of such terms, or other comparable terminology. Such statements include, but are not limited to, statements about the expected benefits of the transaction involving Allscripts, Misys Hospital Systems, Inc. (“MHS”) and Misys, including potential synergies and cost savings, future financial and operating results, and the combined company’s plans and objectives. In addition, statements made in this communication about anticipated financial results, future operational improvements and results or regulatory approvals are also forward-looking statements. Such forward-looking statements are subject to numerous risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from those expressed in or indicated by them. Factors that could cause actual results to differ materially include, but are not limited to: (1) the occurrence of any event, development, change or other circumstances that could give rise to the termination of the merger agreement; (2) the outcome of any legal proceedings that have been or may be instituted against Allscripts, Misys or MHS and others following announcement of entering into the merger agreement; (3) the inability to complete the proposed transaction due to the failure to obtain stockholder or shareholder approval or the failure of any party to satisfy other conditions to completion of the proposed transaction and the receipt of required regulatory approvals; (4) risks that the proposed transaction disrupts current plans and operations and potential difficulties in employee retention as a result of the merger; (5) the ability to recognise the benefits of the merger; and (6) legislative, regulatory and economic developments. Many of the factors that will determine the outcome of the subject matter of this communication are beyond Allscripts’, Misys’ and MHS’ ability to control or predict. Misys can give no assurance that any of the transactions related to the merger will be completed or that the conditions to the merger will be satisfied. Misys undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Misys is not responsible for updating the information contained in this communication beyond the published date, or for changes made to this communication by wire services or Internet service providers.

This communication is being made in respect of the proposed business combination involving Allscripts, Inc. (“Allscripts”) and Misys Healthcare Systems LLC (“MHS”), a wholly owned subsidiary of Misys plc (“Misys”). In connection with this proposed transaction, Allscripts intends to file with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement, a definitive proxy statement and other related materials, and Misys intends to file a shareholder circular with the Financial Services Authority in the United Kingdom. The definitive proxy statement will be mailed to the stockholders of Allscripts, and the shareholder circular will be mailed to the shareholders of Misys. BEFORE MAKING ANY DECISION WITH RESPECT TO THE PROPOSED TRANSACTION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE DOCUMENTS AND OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED TRANSACTION. Investors and security holders can obtain copies of Allscripts’ materials (and all other offer documents filed with the SEC) when available, at no charge on the SEC’s website: www.sec.gov. Copies can also be obtained at no charge by directing a request for such materials to Allscripts at 222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654, Attention: Lee Shapiro, Secretary, or to Misys at 125 Kensington High Street, London W8 5SF, United Kingdom, Attention: Group General Counsel & Company Secretary. Investors and security holders may also read and copy any reports, statements and other information filed by Allscripts with the SEC, at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 or visit the SEC’s website for further information on its public reference room. Allscripts’ directors, executive officers and other members of management and employees may, under the rules of the SEC, be deemed to be participants in the solicitation of proxies from the stockholders of Allscripts in favor of the proposed transaction. Information about Allscripts, its directors and its executive officers, and their ownership of Allscripts’ securities, is set forth in its proxy statement for the 2007 Annual Meeting of Stockholders of the Company, which was filed with the SEC on April 30, 2007. Additional information regarding the interests of those persons may be obtained by reading the proxy statement and other relevant materials to be filed with the SEC when they become available.

What we are going to cover today

Welcome and Business Performance and Highlights

Mike Lawrie, CEO

Financial Review

Jim Malone, CFO

Phase 2 of Turnaround

Mike Lawrie, CEO

Questions

Turnaround is ahead of schedule

- Revenue* growth 6%.
- Operating profit* growth 37%.
- Adjusted basic EPS from continuing operations** growth 67%.





We are raising targets going forward

Next phase of turnaround is focused on continued execution and building sustainable growth platforms

* Figures quoted on a like for like basis

** Adjusted for exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles and translation exchange differences recycled from reserves.

Misys delivered results ahead of expectations








* Where applicable, figures quoted on a like for like basis exclude exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles, translation exchange differences recycled from reserves, the impact of acquisitions and disposals and are at constant exchange rates.

** Global services is included in divisional results.






*** Adjusted for exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles and translation exchange differences recycled from reserves.

Revenue is recurring with geographic diversity

2008 Revenue Mix



2008 Geographic Mix




Recurring revenue for Group 58%, Banking 47%, TCM 48%, Healthcare 75%. These rates are in line year over year.

Emerging Markets presence year over year saw Banking in line at 53% and TCM increasing from 18% to 22%.

Group including Healthcare indicates 62% of revenues are not exposed to the financial institutions of Western Europe and the Americas

Summary of 2007 projections



- Execute cost savings and productivity improvement
- Invest for the future
- 1-1.5% margin improvement
- Flattish revenues

- 2-4% revenue growth
- Services growth rates of 3-5%
- Treasury & Capital Markets revenue growth
- 2-3% margin improvement

- 4-6+% revenue growth
- Margin expansion to 20%+
- Installed base growth
- Post- turn around financial model
- Benefits of product investment – successfully launch new products
 - SOA (services oriented architecture) for Core Banking
 - New Treasury & Capital Markets products
 - New product offerings for connected communities

Cost savings exceeded targets

“Get fit”


1–2 years

- Execute cost savings and productivity improvement

Invest for the future

1-1.5% margin improvement

Flattish revenues



Reinvestment

- Management systems.
- Products / development.
- Reinvest / rebalance customer facing resources, including services.


Cost Savings

- Procurement savings.
- Development.
- Re-organisation.
- Customer facing.
- Back Office / Off-shoring.

“Get fit”

1–2 years

- Execute cost savings and productivity improvement
- Invest for the future
- 1-1.5% margin improvement
- Flattish revenues



Focus on 3 areas:


1. Global services
2. Products
 - BankFusion
 - Summit
 - Trade Services
 - Banking Front-End
 - Payerpath
3. Processes
 - Sales
 - Support
 - Development
 - Operational

Operating margin improved 300 basis points

“Get fit”


1–2 years

- Execute cost savings and productivity improvement
- Invest for the future
- **1-1.5% margin improvement**
- Flattish revenues



We have increased operating margin 300 basis points to 16% in the last fiscal year on LFL basis.

LFL Operating Profit per FTE Employee




Revenue grew across business units

“Get fit”


1–2 years

- Execute cost savings and productivity improvement
- Invest for the future
- 1-1.5% margin improvement
- **Flattish revenues**



We have grown revenues 6% on a LFL basis with each business showing growth.

Big milestones behind us



What we have achieved to return to growth

1 Cost take out

2 Rebalanced portfolio

3 Capital structure: net debt to net cash

4 New management team

5 Every Business Unit executing a strategy

6 New processes

7 Key partnerships

8 Merger of Allscripts & Misys Healthcare

1 Cost take out

2 Rebalanced portfolio

Cost savings were realised faster than expected.

3 Capital structure: net debt to net cash

4 New management team

5 Every Business Unit executing a strategy

6 New processes

7 Key partnerships

8 Merger of Allscripts & Misys Healthcare

1 Cost take out

2 Rebalanced portfolio

3 Capital structure: net debt to market cap

4 New management team

5 Every Business Unit executing strategy

6 New processes

7 Key partnerships

8 Merger of Allscripts & Misys Health

- **Sesame divestiture**
- **Healthcare divestitures**
- **iMedica investment**
- **Strategic development partnerships**
- **New Emerging Markets region**
- **Global services as a line of business**
- **Open Source division created**
- **Banking and TCM split but still optimising synergies**

- 1 Cost take out
- 2 Rebalanced portfolio
- 3 Capital structure: net debt to net cash**

- 4 New management team
- 5 Every Business Unit executing a
- 6 New processes
- 7 Key partnerships
- 8 Merger of Allscripts & Misys Healthcare

Successful divestitures allowed us to restructure our balance sheet from a net debt to a net cash position with leverage flexibility; Allscripts-Misys Healthcare merger funded by replacing existing instruments and also ValueAct support.

- 1 Cost take out
- 2 Rebalanced portfolio
- 3 Capital Structure: net debt to net cash
- 4 New management team**
- 5 Every Business Unit executing a
- 6 New processes
- 7 Key partnerships
- 8 Merger of Allscripts & Misys Healthcare

We replaced 80% of senior executives and 75% of second line managers.

1 Cost take out

2 Rebalanced portfolio

3 Capital structure: net debt to net

4 New management team

5 Every Business Unit executing a strategy

6 New processes

7 Key partnerships

8 Merger of Allscripts & Misys Healthcare

Each business unit is measured every 2 weeks against its strategic objectives and financial results in our Operating Committee and compensation is aligned with our strategy.

1 Cost take out

2 Rebalanced portfolio

3 Capital structure: net debt to net

4 New management team

5 Every Business Unit executing a strategy

6 New processes

7 Key partnerships

8 Merger of Allscripts & Misys Healthcare

We have invested and will continue to invest in Sales, Support, Development, Financial Systems and HR Systems to better serve our customers, investors and employees.

1 Cost take out

2 Rebalanced portfolio

3 Capital structure: net debt to net cash

4 New management team

5 Every Business Unit executing a

6 New processes

7 Key partnerships

8 Merger of Allscripts & Misys Healthcare

- Digital China
- HCL
- SAP
- Symphony
- Wipro

- 1 Cost take out
- 2 Rebalanced portfolio
- 3 Capital structure: net debt to net cash
- 4 New management team
- 5 Every Business Unit executing a
- 6 New processes
- 7 Key partnerships

The Allscripts merger announced in March 2008 will improve growth in our Healthcare business and better monetise our respective installed bases through cross-selling the broader product lines; Misys plc will accelerate growth.

8 Merger of Allscripts & Misys Healthcare

Total Order Intake

| <i>£millions</i> | LFL 2007 | LFL 2008 | Growth |
|------------------------|-------------|-------------|-----------|
| Total | <u>242</u> | <u>259</u> | <u>7%</u> |
| ILF (including ASP) | 110 | 114 | 4% |
| Global services | 72 | 83 | 16% |
| Transaction processing | 60 | 62 | 4% |
| Banking | 77 | 83 | 8% |
| TCM | 63 | 73 | 16% |
| Healthcare | 102 | 103 | 2% |

Total Order Intake is presented on a gross basis reflecting contracts signed during the fiscal year. Prior year amounts were previously reported on a net basis, however for comparative purposes 2007 has been restated to a gross basis.

Total Order Intake – detailed format by unit



| <i>£millions</i> | LFL 2007 | LFL 2008 | Growth |
|---------------------------------------|-------------|-------------|--------|
| Banking | | | |
| ILF | 44 | 46 | 5% |
| Global services | 33 | 37 | 13% |
| Total | 77 | 83 | 8% |
| Treasury & Capital Markets | | | |
| ILF | 40 | 42 | 4% |
| Global services | 23 | 31 | 36% |
| Total | 63 | 73 | 16% |
| Healthcare | | | |
| ILF | 26 | 21 | (17%) |
| Misys MyWay (ASP) | - | 5 | |
| Subtotal | 26 | 26 | 1% |
| Global services | 16 | 15 | (5%) |
| Payerpath | 60 | 62 | 4% |
| Total | 102 | 103 | 2% |

Figures quoted on a like for like basis



Banking Financial Results

- Total Order Intake £83m, up 8%.
- Total revenue £160m, up 5%.
- Operating profit £19m, up 2%.
- Operating margin 12%, flat.

Banking Financial Trends

- Good growth in services revenue up 19% - new offerings well received.
- Geographic diversity of revenue base.
 - Limited exposure to Western Regions.
 - 53% revenue from Emerging Markets.
- Continued low level of customer attrition.
- 47% recurring revenue.

Banking Revenue (FY08 % total) - £160m



Banking Customers

- 1,200+ customers, including all of world's top 50 banks.
- Good growth in Eastern Europe and other Emerging Markets.
 - 5 new customers from Emerging Markets.
 - 155 go lives.
 - Selected new customers:
 - Misys Equation: Public Bank Berhad, SOYUZ Bank.
 - Islamic Banking: Albaraka Banking Group.
- Highly diversified customer base, with top 10 customers generating 30% of revenues.

Banking Growth Platform

- Misys BankFusion development on track.
 - Standard Bank of South Africa, a Tier 1 Bank, is contracted to be first implementation.
- Building services Upgrade Factory
- Investing in Trade Services and retail banking front-end product lines.



TCM Financial Results

- Total Order Intake £73m, up 16%.
- Total revenue £141m, up 13%.
- Operating profit £32m, up 10%.
- Operating margin 23%, flat.

TCM Financial Trends

- Services revenue up 41% year on year.
- Flat margin reflects increasing investment in the business.
- 48% recurring revenue.
- Growing presence in Emerging Markets.

TCM Revenue (FY08 % total) - £141m



TCM Customers


- 1,000+ customers.
- Highly diversified customer base, with top 10 customers generating 18% of revenues.
- 20 new wins include Chinese and Indian customers. New clients during the year include Axis Bank, Temasek, Wing Hang Bank, China Everbright Bank and Credit Union Central of Manitoba.
 - 15 new customers from Emerging Markets.
 - China, India, Asia and the Middle East are experiencing particularly rapid growth.

TCM Growth Platform

- Extending hosted platforms for all TCM products.
- Investing in SOA/Summit architecture.
- Investing in direct salesforce, services and distribution partnerships in new geographies.


Healthcare Financial Results

- Total Order Intake £103m, up 2%.
- Total revenue £191m, up 2%.
- Growth in recurring revenue demonstrating good customer loyalty.
- Operating profit £39m, up 85%.
- Operating margin 20%, up 900 basis points.



Healthcare Growth Platform

- Restructuring completed and business stabilised.
- Investment in iMedica – Misys MyWay sales off to a strong start.
 - MyWay customers represent shift from on-premises to hosted model.
- Payerpath showing good growth in transaction processing.



Global services (included in divisional numbers)

- Total Order Intake up 16% with growth in Banking and TCM.
- Revenue growth of 19% in Banking and 41% in TCM offset 8% decline in Healthcare.
- New management team in place.
- Launched new global offerings with positive customer response.
- Partnering to expand delivery capability.

Financial Review

Jim Malone, EVP/CFO

2008

- Revenue* £492m up 6%.
- Operating profit* £81m up 37%.
- Adjusted basic EPS from continuing operations** 12.6p up 67%.
- Operating margin* 16% up 300 basis points.

* Figures quoted on a like for like basis

** Adjusted for exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles and translation exchange differences recycled from reserves.

Business results

Like for like

| <i>£ millions</i> | Revenue | | | Operating profit | | | Margin | |
|----------------------------|---------|------|--------|------------------|------|--------|--------|------|
| | 2007 | 2008 | Growth | 2007 | 2008 | Growth | 2007 | 2008 |
| Banking | 151 | 160 | 5% | 19 | 19 | 2% | 12% | 12% |
| Treasury & Capital Markets | 125 | 141 | 13% | 29 | 32 | 10% | 23% | 23% |
| Healthcare | 188 | 191 | 2% | 21 | 39 | 85% | 11% | 20% |
| Central Services | - | - | | (10) | (9) | | | |
| Continuing operations | 464 | 492 | 6% | 59 | 81 | 37% | 13% | 16% |

Figures quoted on a like for like basis exclude exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles, translation exchange differences recycled from reserves, the impact of acquisitions and disposals and are at constant exchange rates.

| <i>£ millions</i> | As reported | Exceptional items | Embedded derivatives | Amortisation of acquired intangibles | 2008 LFL | 2007 LFL |
|--|--------------------|----------------------|-------------------------|--|---------------------|---------------------|
| Revenue | | | | | | |
| Banking | 160 | - | - | - | 160 | 151 |
| Treasury & Capital Markets | 141 | - | - | - | 141 | 125 |
| Healthcare | 191 | - | - | - | 191 | 188 |
| Continuing | 492 | - | - | - | 492 | 464 |
| Operating profit | | | | | | |
| Banking | 10 | 6 | 1 | 2 | 19 | 19 |
| Treasury & Capital Markets | 31 | 1 | - | - | 32 | 29 |
| Healthcare | 31 | 7 | - | 1 | 39 | 21 |
| Central Services | (20) | 11 | - | - | (9) | (10) |
| Continuing | 52 | 25 | 1 | 3 | 81 | 59 |
| Net finance costs | (3) | - | - | - | (3) | (15) |
| Profit before taxation | 49 | 25 | 1 | 3 | 78 | 44 |
| Taxation | (14) | (3) | - | - | (17) | (9) |
| Profit from discontinued operations | 78 | (71) | - | - | 7 | 33 |
| Retained earnings | 113 | (49) | 1 | 3 | 68 | 68 |

Exceptional items

| <i>£ millions</i> | 2007 | 2008 |
|---|------|------|
| Continuing operations | | |
| <i>Turnaround programme</i> | | |
| Consultancy | 6 | 7 |
| Relocation / redundancy | 3 | 8 |
| Property costs / UK office rationalisation | 1 | 4 |
| Asset write down / impairment | 20 | 2 |
| Retention, recruitment and dual running | - | 1 |
| Other | 1 | 2 |
| | 31 | 24 |
| Adjustment to goodwill | - | 1 |
| Terminated offer process | 7 | - |
| Profit on disposal of business | (1) | - |
| Total continuing operations | 37 | 25 |
| Discontinued operations | | |
| Turnaround programme | 3 | - |
| Profit on disposal of business and impairment of goodwill | 17 | (74) |
| Total discontinued operations | 20 | (74) |
| Total exceptional items before tax | 57 | (49) |

Banking

Like for like

| <i>£ millions</i> | 2007 | | | 2008 | | | Change | | |
|---------------------------|------|------|-------|------|------|-------|--------|-------|------|
| | H1 | H2 | FY | H1 | H2 | FY | H1 | H2 | FY |
| Total Order Intake | 38 | 39 | 77 | 39 | 44 | 83 | 5% | 11% | 8% |
| ILF | 19 | 25 | 44 | 19 | 27 | 46 | 4% | 5% | 5% |
| Global services | 19 | 14 | 33 | 20 | 17 | 37 | 6% | 21% | 13% |
| Revenue | | | | | | | | | |
| ILF | 19 | 24 | 43 | 19 | 24 | 43 | (3%) | - | (1%) |
| Maintenance | 36 | 37 | 73 | 37 | 39 | 76 | 1% | 5% | 3% |
| Global services | 18 | 17 | 35 | 19 | 22 | 41 | 8% | 30% | 19% |
| Total revenue | 73 | 78 | 151 | 75 | 85 | 160 | 2% | 9% | 5% |
| Total costs | (66) | (66) | (132) | (67) | (74) | (141) | (1%) | 12% | 6% |
| Adjusted operating profit | 7 | 12 | 19 | 8 | 11 | 19 | 17% | (16%) | 2% |
| Margin | 9% | 15% | 12% | 11% | 13% | 12% | | | |

Figures quoted on a like for like basis exclude exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles, translation exchange differences recycled from reserves, the impact of acquisitions and disposals and are at constant exchange rates.

Treasury & Capital Markets

Like for like



| <i>£ millions</i> | 2007 | | | 2008 | | | Change | | |
|---------------------------|------|------|------|------|------|-------|--------|-----|------|
| | H1 | H2 | FY | H1 | H2 | FY | H1 | H2 | FY |
| Total Order Intake | 26 | 37 | 63 | 29 | 44 | 73 | 8% | 21% | 16% |
| ILF | 17 | 23 | 40 | 14 | 28 | 42 | (20%) | 21% | 4% |
| Global services | 9 | 14 | 23 | 15 | 16 | 31 | 59% | 19% | 36% |
| Revenue | | | | | | | | | |
| ILF | 19 | 22 | 41 | 17 | 28 | 45 | (9%) | 31% | 12% |
| Maintenance | 26 | 26 | 52 | 27 | 29 | 56 | 3% | 11% | 7% |
| Global services | 9 | 11 | 20 | 13 | 15 | 28 | 42% | 40% | 41% |
| Other | 6 | 6 | 12 | 6 | 6 | 12 | (3%) | - | (2%) |
| Total revenue | 60 | 65 | 125 | 63 | 78 | 141 | 4% | 22% | 13% |
| Total costs | (47) | (49) | (96) | (50) | (59) | (109) | 6% | 23% | 14% |
| Adjusted operating profit | 13 | 16 | 29 | 13 | 19 | 32 | (1%) | 18% | 10% |
| Margin | 21% | 25% | 23% | 20% | 25% | 23% | | | |

Figures quoted on a like for like basis exclude exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles, translation exchange differences recycled from reserves, the impact of acquisitions and disposals and are at constant exchange rates.

Healthcare

Like for like

| <i>£ millions</i> | 2007 | | | 2008 | | | Change | | |
|---------------------------|-----------|-----------|------------|-----------|-----------|------------|-------------|-----------|-----------|
| | H1 | H2 | FY | H1 | H2 | FY | H1 | H2 | FY |
| Total Order Intake | <u>50</u> | <u>52</u> | <u>102</u> | <u>48</u> | <u>55</u> | <u>103</u> | <u>(4%)</u> | <u>7%</u> | <u>2%</u> |
| ILF | 14 | 12 | 26 | 9 | 12 | 21 | (32%) | - | (17%) |
| Misys MyWay (ASP) | - | - | - | 2 | 3 | 5 | - | - | - |
| Subtotal | 14 | 12 | 26 | 11 | 15 | 26 | (19%) | 23% | 1% |
| Global services | 8 | 8 | 16 | 6 | 9 | 15 | (23%) | 15% | (5%) |
| Payerpath | 28 | 32 | 60 | 31 | 31 | 62 | 9% | - | 4% |
| Revenue | | | | | | | | | |
| ILF | 12 | 12 | 24 | 12 | 12 | 24 | (6%) | 3% | (2%) |
| Maintenance | 33 | 34 | 67 | 35 | 36 | 71 | 5% | 7% | 6% |
| Global services | 8 | 7 | 15 | 7 | 7 | 14 | (16%) | - | (8%) |
| Transaction processing | 34 | 35 | 69 | 35 | 37 | 72 | 7% | 2% | 4% |
| Hardware | 6 | 7 | 13 | 4 | 6 | 10 | (36%) | (2%) | (20%) |
| Total revenue | 93 | 95 | 188 | 93 | 98 | 191 | (1%) | 4% | 2% |
| Total costs | (82) | (85) | (167) | (75) | (77) | (152) | (8%) | (9%) | (9%) |
| Adjusted operating profit | 11 | 10 | 21 | 18 | 21 | 39 | 56% | 120% | 85% |
| Margin | 12% | 11% | 11% | 19% | 22% | 20% | | | |

Figures quoted on a like for like basis exclude exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles, translation exchange differences recycled from reserves, the impact of acquisitions and disposals and are at constant exchange rates.

experience, solutions, results

Global services

Like for like (included in divisional figures)



| <i>£ millions</i> | 2007 | | | 2008 | | | Change | | |
|---------------------------|-----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|
| | H1 | H2 | FY | H1 | H2 | FY | H1 | H2 | FY |
| Order intake | | | | | | | | | |
| Banking | 19 | 14 | 33 | 20 | 17 | 37 | 6% | 21% | 13% |
| TCM | 9 | 14 | 23 | 15 | 16 | 31 | 59% | 19% | 36% |
| Healthcare | 8 | 8 | 16 | 6 | 9 | 15 | (23%) | 15% | (5%) |
| Total Order Intake | 36 | 36 | 72 | 41 | 42 | 83 | 13% | 19% | 16% |
| Revenue | | | | | | | | | |
| Banking | 18 | 17 | 35 | 19 | 22 | 41 | 8% | 30% | 19% |
| TCM | 9 | 11 | 20 | 13 | 15 | 28 | 42% | 40% | 41% |
| Healthcare | 8 | 7 | 15 | 7 | 7 | 14 | (16%) | - | (8%) |
| Total revenue | 35 | 35 | 70 | 39 | 44 | 83 | 12% | 27% | 19% |

Figures quoted on a like for like basis exclude exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles, translation exchange differences recycled from reserves, the impact of acquisitions and disposals and are at constant exchange rates.

Cashflow conversion from continuing operations



| <i>£ millions</i> | 2007 | 2008 |
|--|-------------|-------------|
| Profit Before Tax and Interest on continuing operations | 19 | 52 |
| Depreciation, amortisation and impairment | 36 | 14 |
| Capitalised expenditure, including capitalised R&D | (21) | (34) |
| Working capital movements | (4) | (49) |
| Share-based payments and pension adjustment | 4 | 6 |
| Other | 0 | 3 |
| Cash before financing, tax and dividend payments | 34 | (8) |
| Tax | (15) | (18) |
| Interest | (16) | (4) |
| Dividends | (35) | (37) |
| Purchase of own shares and issue of options | 6 | - |
| Total cashflow before discontinued operations and acquisition/disposal activity | (26) | (67) |
| Discontinued | 30 | 2 |
| Acquisitions/disposals | (4) | 177 |
| Total Cashflow | - | 112 |
| Foreign exchange and other non cash movements | 4 | 5 |
| Opening Net Debt | (95) | (91) |
| Closing Net Debt | (91) | 26 |

Working capital analysis (continuing operations)



| <i>£ millions</i> | 2007 | 2008 | (Increase)/ decrease |
|------------------------------|-------|-------|-------------------------|
| Assets | | | |
| Accounts receivable | 59 | 82 | (23) |
| Accrued income | 20 | 36 | (16) |
| Prepayments and contract WIP | 11 | 22 | (11) |
| Other receivables | 10 | 12 | (2) |
| | 100 | 152 | (52) |
| Liabilities | | | |
| Trade and other payables | (105) | (109) | 4 |
| Deferred income | (90) | (93) | 3 |
| Provisions | (17) | (18) | 1 |
| | (202) | (202) | 8 |
| Foreign exchange and other | | | (5) |
| Working capital movement | | | (49) |

Accounts receivable ageing

| <i>£ millions</i> | 2007 | 2008 |
|-------------------|------|------|
| 0 - 30 days | 35 | 49 |
| 30 - 60 days | 7 | 14 |
| 60 - 90 days | 5 | 7 |
| 90 - 120 days | 4 | 4 |
| 120 days + | 8 | 8 |
| | 59 | 82 |


Accrued income: billings due

| <i>£ millions</i> | 2007 | 2008 |
|-------------------|------|------|
| 0 - 3 months | 9 | 13 |
| 3 - 6 months | 5 | 11 |
| 6 -12 months | 5 | 9 |
| 12 months + | 1 | 3 |
| | 20 | 36 |

Phase 2 of Turnaround

Mike Lawrie, Chief Executive

We are moving into Win More phase



- Execute cost savings and productivity improvement
- Invest for the future
- 1-1.5% margin improvement
- Flattish revenues

- 2-4% revenue growth
- Services growth rates of 3-5%
- Treasury & Capital Markets revenue growth
- 2-3% margin improvement

- 4-6+% revenue growth
- Margin expansion to 20%+
- Installed base growth
- Post- turnaround financial model
- Benefits of product investment – successfully launch new products
 - SOA (services oriented architecture) for Core Banking
 - New Treasury & Capital Markets products
 - New product offerings for connected communities

“Win more”

1–2 years

- **2-4% revenue growth**
- Services growth rates of 3-5%
- Treasury & Capital Markets revenue growth
- 2-3% margin improvement

Revised target revenue expectations to 5-8% in next phase.


“Win more”


1–2 years

- 2-4% revenue growth
- Services growth rates of 3-5%
- Treasury & Capital Markets revenue growth
- 2-3% margin improvement

Revised target revenue expectations to 5-8% in next phase.

Revised services growth target rates to 15-18% in next phase.





Monetise installed base in Banking, TCM and Healthcare

Investment in New Products / Solutions

- Global services.
- BankFusion.
- Summit.
- Trade Services.
- Banking Front-End.
- Islamic Banking.
- Payerpath.

Investment in Markets

- Emerging Markets (China, India, MEA).
- Sales and Services.
- Winning Partnerships.
- US Healthcare industry (Allscripts-Misys Healthcare merger).

Continued Investment in Process

- Sales Support.
- Development.
- Operational.
 - HR.
 - Quote to Cash.

Investment in Innovation

- Open Source Connect.
- Open Source Carbon Portal.

- Received US antitrust clearance in May.
- Completed carve-out financial audits.
- Filed the US proxy in June, now under review with SEC, initial comments received.
- Preparing the circular for Misys plc shareholders.
- Will convene meetings of both Misys plc and Allscripts shareholders.
- Expected to close in September 2008.



Turnaround is ahead of schedule

- Revenue* growth 6%.
- Operating profit* growth 37%.
- Adjusted basic EPS from continuing operations** growth 67%.

We are raising targets going forward

Next phase of turnaround is focused on continued execution and building sustainable growth platforms

* Figures quoted on a like for like basis

** Adjusted for exceptional items, gains and losses on embedded derivatives, amortisation of acquired intangibles and translation exchange differences recycled from reserves.

Questions

Appendices / For information

Statutory reporting summary

| <i>£ millions</i> | 2007 | 2008 |
|--------------------------|-------|-------|
| Revenue* | 469 | 492 |
| Operating margin* | 4% | 11% |
| Operating profit* | 19 | 52 |
| Basic earnings per share | 3.1p | 23.5p |
| Dividends per share | 7.53p | 7.91p |

* Continuing operations

experience, solutions, results

| 2007 <i>£ millions</i> | As reported | Exceptional items | Embedded derivatives | Amortisation of acquired intangibles | FX | LFL |
|--|--------------------|-------------------|----------------------|--------------------------------------|-----|-------------|
| Revenue | | | | | | |
| Banking | 148 | - | - | - | 3 | 151 |
| Treasury & Capital Markets | 125 | - | - | - | - | 125 |
| Healthcare | 196 | - | - | - | (8) | 188 |
| Continuing | 469 | - | - | - | (5) | 464 |
| Operating profit | | | | | | |
| Banking | 6 | 11 | - | 3 | (1) | 19 |
| Treasury & Capital Markets | 28 | - | - | - | 1 | 29 |
| Healthcare | 8 | 13 | - | 1 | (1) | 21 |
| Central costs | (23) | 13 | - | - | - | (10) |
| Continuing | 19 | 37 | - | 4 | (1) | 59 |
| Net finance costs | (15) | - | - | - | - | (15) |
| Profit before taxation | 4 | 37 | - | 4 | (1) | 44 |
| Taxation | (3) | (6) | - | - | - | (9) |
| Profit from discontinued operations | 14 | 20 | - | - | (1) | 33 |
| Retained earnings | 15 | 51 | - | 4 | (2) | 68 |

Exchange rates

| | Closing balance | | Average for the year | |
|-----------|-----------------|-------------|----------------------|-------------|
| | May 2007 | May 2008 | May 2007 | May 2008 |
| US dollar | 1.98 | 1.98 | 1.92 | 2.00 |
| | <i>100</i> | <i>100</i> | <i>100</i> | <i>104</i> |
| Euro | 1.47 | 1.27 | 1.48 | 1.38 |
| | <i>100</i> | <i>86</i> | <i>100</i> | <i>94</i> |

Tax rate on continuing operations

| <i>£millions</i> | 2007 | 2008 |
|---|------|------|
| Operating profit before exceptional items | 56 | 78 |
| Other adjustments* | 4 | 3 |
| Finance costs | (15) | (3) |
| Adjusted profit before tax | 45 | 78 |
| Tax charge on operating items | 9 | 17 |
| Tax rate | 20% | 22% |
| Statutory tax charge on continuing operations | 3 | 14 |
| Add back tax credit on exceptional items | 6 | 3 |
| Tax charge on operating items | 9 | 17 |

* Gains and losses on embedded derivatives, amortisation of acquired intangibles and translation exchange differences recycled from reserves.

Debtor days (continuing operations)

| <i>£ millions</i> | May 2007 | May 2008 |
|--------------------------------------|----------|------------|
| Net trade receivables | 59 | 82 |
| Accrued income | 20 | 36 |
| | 79 | 118 |
| Debtor days based on: | | |
| Trade receivables | 29 | 38 |
| Trade receivables and accrued income | 44 | 68 |



experience, solutions, results